CA2571055C - Compounds and methods for treating seizure and paroxysmal disorders - Google Patents

Compounds and methods for treating seizure and paroxysmal disorders Download PDF

Info

Publication number
CA2571055C
CA2571055C CA2571055A CA2571055A CA2571055C CA 2571055 C CA2571055 C CA 2571055C CA 2571055 A CA2571055 A CA 2571055A CA 2571055 A CA2571055 A CA 2571055A CA 2571055 C CA2571055 C CA 2571055C
Authority
CA
Canada
Prior art keywords
glucose
deoxy
pharmaceutical composition
epilepsy
antiglycolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2571055A
Other languages
English (en)
French (fr)
Other versions
CA2571055A1 (en
Inventor
Steven M. Kriegler
Avtar S. Roopra
Thomas P. Sutula
Carl E. Stafstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CA2571055A1 publication Critical patent/CA2571055A1/en
Application granted granted Critical
Publication of CA2571055C publication Critical patent/CA2571055C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2571055A 2004-06-17 2005-06-17 Compounds and methods for treating seizure and paroxysmal disorders Active CA2571055C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58043604P 2004-06-17 2004-06-17
US60/580,436 2004-06-17
PCT/US2005/021845 WO2006002121A2 (en) 2004-06-17 2005-06-17 Compounds and methods for treating seizure and paroxysmal disorders

Publications (2)

Publication Number Publication Date
CA2571055A1 CA2571055A1 (en) 2006-01-05
CA2571055C true CA2571055C (en) 2011-11-29

Family

ID=35427194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2571055A Active CA2571055C (en) 2004-06-17 2005-06-17 Compounds and methods for treating seizure and paroxysmal disorders

Country Status (11)

Country Link
US (1) US7795227B2 (ko)
EP (1) EP1885379B1 (ko)
JP (1) JP2008502705A (ko)
KR (1) KR20070034591A (ko)
CN (1) CN1972697A (ko)
AU (2) AU2005258021B2 (ko)
BR (1) BRPI0512161A (ko)
CA (1) CA2571055C (ko)
ES (1) ES2590259T3 (ko)
IL (1) IL179864A0 (ko)
WO (1) WO2006002121A2 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
ES2590259T3 (es) 2004-06-17 2016-11-21 Wisconsin Alumni Research Foundation Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos
AU2006214489A1 (en) * 2005-02-14 2006-08-24 Wisconsin Alumni Research Foundation Metabolic-based methods for modulating gene expression
US20060217303A1 (en) * 2005-03-25 2006-09-28 Wisconsin Alumni Research Foundation Compounds and Methods for Treating Seizure Disorders
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US20080089981A1 (en) * 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
EP2394647A1 (en) 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
AU2008211600B8 (en) * 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
MX2009008165A (es) * 2007-02-01 2009-08-12 Iams Company Metodo para disminuir la inflamacion y el esfuerzo oxidante en mamiferos.
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2600875A1 (en) 2010-08-04 2013-06-12 Wisconsin Alumni Research Foundation Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
JP5888746B2 (ja) * 2010-08-24 2016-03-22 国立大学法人 宮崎大学 マトリックスメタロプロテアーゼ活性抑制組成物
CN106998748A (zh) 2014-12-08 2017-08-01 雀巢产品技术援助有限公司 用于治疗癫痫的包含中链甘油三酯的组合物和方法
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
CN106668035A (zh) * 2017-01-24 2017-05-17 中南大学湘雅三医院 一种抗癫痫药物组合物
CN115884766A (zh) * 2020-05-29 2023-03-31 睿升公司 用于使用中链甘油三酯治疗婴儿痉挛的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6553994A (en) * 1993-03-31 1994-10-24 Trustees Of The University Of Pennsylvania, The Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor
US5643883A (en) * 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6620850B2 (en) 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US7145032B2 (en) * 2002-02-23 2006-12-05 Washington University Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto
RU2005125428A (ru) 2003-01-10 2006-03-10 Тресхолд Фармасьютикалз, Инк. (Us) Лечение рака 2-деоксиглюкозой
BRPI0406667A (pt) * 2003-01-10 2005-12-20 Threshold Pharmaceuticals Inc Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
CN1771043A (zh) 2003-01-10 2006-05-10 施瑞修德制药公司 利用2－脱氧葡萄糖治疗癌症
US20060172953A1 (en) * 2003-01-17 2006-08-03 Threshold Pharmaceuticals Inc. Treatment of benign prostatic hyperplasia using energolytic agents
WO2004064736A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
RU2005126042A (ru) 2003-01-17 2006-02-27 Тресхолд Фармасьютикалз, Инк. (Us) Лечение доброкачественной гиперплазии простаты
ES2590259T3 (es) 2004-06-17 2016-11-21 Wisconsin Alumni Research Foundation Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos
US20070292478A1 (en) 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
GB0419990D0 (en) 2004-09-09 2004-10-13 Suisse Electronique Microtech Marking articles
AU2006214489A1 (en) 2005-02-14 2006-08-24 Wisconsin Alumni Research Foundation Metabolic-based methods for modulating gene expression
US20060217303A1 (en) * 2005-03-25 2006-09-28 Wisconsin Alumni Research Foundation Compounds and Methods for Treating Seizure Disorders
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders

Also Published As

Publication number Publication date
JP2008502705A (ja) 2008-01-31
BRPI0512161A (pt) 2008-02-12
AU2005258021A1 (en) 2006-01-05
CN1972697A (zh) 2007-05-30
WO2006002121A3 (en) 2006-03-02
AU2009201069A1 (en) 2009-04-09
EP1885379B1 (en) 2016-07-20
ES2590259T3 (es) 2016-11-21
WO2006002121A2 (en) 2006-01-05
CA2571055A1 (en) 2006-01-05
US20060088517A1 (en) 2006-04-27
KR20070034591A (ko) 2007-03-28
EP1885379A2 (en) 2008-02-13
IL179864A0 (en) 2007-07-04
AU2005258021B2 (en) 2008-12-18
US7795227B2 (en) 2010-09-14

Similar Documents

Publication Publication Date Title
CA2571055C (en) Compounds and methods for treating seizure and paroxysmal disorders
US20060287253A1 (en) Compounds and methods for treating seizure disorders
US20060217303A1 (en) Compounds and Methods for Treating Seizure Disorders
JP5690261B2 (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
EP2240170B1 (en) Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
AU2019265002B2 (en) Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
JP7217259B2 (ja) てんかん及び関連疾患を患う患者の予防及び治療のためのメセンブレノール及び／又はメセンブラノール
US20100197610A1 (en) Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
MXPA00012808A (es) El uso de analogo de acido valproico para tratamiento y prevencion de migrana y enfermedad afectiva.
US20070098777A1 (en) Pharmaceutical or Food Composition for Treatment or Prevention of Brain Edema
Mu et al. NBQX treatment improves mitochondrial function and reduces oxidative events after spinal cord injury
EP0217258B1 (en) The use of choline or choline releasing compounds for reducing the perception of fatigue
Zhou et al. Diazepam monotherapy or diazepam-ketamine dual therapy at different time points terminates seizures and reduces mortality in a status epilepticus animal model
JP7570924B2 (ja) 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法
RU2664668C1 (ru) Антиаритмическое лекарственное средство
JPH09255579A (ja) 痴呆治療剤
EP0125900A1 (en) A pharmaceutical composition for use in treating neurological disease or aging
MXPA00011686A (es) Composicion que comprende acido beta-hidroxi-beta-metilbutirico y al menos un aminoacido y metodos de uso

Legal Events

Date Code Title Description
EEER Examination request